Want to see AARD full AI Analyst Report?
Aardvark Therapeutics, Inc. (AARD) Stock Statistics & Valuation Metrics
Total Valuation
Aardvark Therapeutics, Inc. has a market cap or net worth of $29.76M. The enterprise value is $52.64M.
- Market Cap
- $29.76M
- Enterprise Value
- $52.64M
Share Statistics
Aardvark Therapeutics, Inc. has 21,884,846 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 21,884,846
- Owned by Insiders
- 14.60%
- Owned by Institutions
- 11.42%
Financial Efficiency
Aardvark Therapeutics, Inc.’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -58.58%.
- Return on Equity (ROE)
- -0.54
- Return on Assets (ROA)
- -0.49
- Return on Invested Capital (ROIC)
- -58.58%
- Return on Capital Employed (ROCE)
- -0.59
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.06M
- Employee Count
- 28
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Aardvark Therapeutics, Inc. is -0.37. Aardvark Therapeutics, Inc.’s PEG ratio is 0.01.
- PE Ratio
- -0.37
- PS Ratio
- 0.00
- PB Ratio
- 0.35
- Price to FCF
- -0.38
- Price to Operating Cash Flow
- -0.38
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Aardvark Therapeutics, Inc. had revenue of 0 and earned -57.59M in profits. Earnings per share was -2.64.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -62.73M
- Pretax Income
- -57.59M
- Net Income
- -57.59M
- EBITDA
- -57.55M
- Earnings Per Share (EPS)
- -2.64
Cash Flow
In the last 12 months, operating cash flow was -69.41M and capital expenditures -4,000, giving a free cash flow of -69.41M billion.
- Operating Cash Flow
- -69.41M
- Free Cash Flow
- -69.41M
- Free Cash Flow per Share
- -3.18
Dividends & Yields
Aardvark Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -256.19%
- Earnings Yield
- -258.41%
Stock Price Statistics
- Beta
- 2.56
- 52-Week Price Change
- -88.77%
- 50-Day Moving Average
- 4.75
- 200-Day Moving Average
- 6.15
- Relative Strength Index (RSI)
- 24.88
- Average Volume (3m)
- 583.23K
Important Dates
Aardvark Therapeutics, Inc. upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Aardvark Therapeutics, Inc. as a current ratio of 10.61, with Debt / Equity ratio of 0.41%
- Current Ratio
- 10.61
- Quick Ratio
- 10.61
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.81
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Aardvark Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Aardvark Therapeutics, Inc. EV to EBITDA ratio is 0.66, with an EV/FCF ratio of 0.66.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.66
- EV to Free Cash Flow
- 0.66
- EV to Operating Cash Flow
- 0.66
Balance Sheet
Aardvark Therapeutics, Inc. has $73.87M in cash and marketable securities with $677.00K in debt, giving a net cash position of $73.19M billion.
- Cash & Marketable Securities
- $73.87M
- Total Debt
- $677.00K
- Net Cash
- $73.19M
- Net Cash Per Share
- $3.34
- Tangible Book Value Per Share
- $3.42
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Aardvark Therapeutics, Inc. is $3.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $3.00
- Price Target Upside
- 150.00% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 8
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -89.45%
Scores
- Smart Score
- ―
- AI Score
- 45
